INVIZYNE Trademark
INVIZYNE is a USPTO trademark filed by Invizyne Technologies, Inc.. Status: Pending.
Trademark Facts
| Mark | INVIZYNE |
|---|---|
| Serial Number | 90287671 |
| Status | Pending |
| Filing Date | 2020-10-29 |
| Mark Type | Combined |
| Nice Classes | 003 (Cosmetics), 004 (Lubricants & Fuels), 005 (Pharmaceuticals), 030 (Staple Foods) |
| Owner | Invizyne Technologies, Inc. |
| Attorney of Record | Thomas C. Lundin Jr. |
| Prosecution Events | 43 |
| Latest Event | GNRN on 2026-03-18 |
Goods & Services
Fragrances; terpenes for use in essential oils | Biofuels; fuels, biofuels and biodiesels based on energy-producing organic compounds, namely, terpenes, isoprenoids, alcohols, fatty acids, esters, alkanes, and alkenes | Pharmaceuticals, namely, alcohols, esters, alkaloids, polyketides, steroids, isoprenoids, and non-ribosomal peptides, for use the treatment of pain, neuropathic pain, cancer pain, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, multiple sclerosis, spinal cord injury, bladder disfunction, peripheral neuropathy, spasticity, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, post-traumatic stress disorder, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse, epilepsy, convulsions, seizures, Dravet syndrome, Lennox-Gastaut syndrome, intractable childhood epilepsy with generalized tonic-clonic seizures, generalized epilepsy with febrile seizures plus, Doose syndrome, chromosome disorders, and metabolic disorders; anti-inflammatories; analgesics; nutraceuticals for use as a dietary supplement; dietary and nutritional supplements; none of the foregoing containing CBD, cannabinoids or tryptamines | Flavor enhancers for use in food and beverage products
Recent Prosecution Activity
| Date | Document | Type |
|---|---|---|
| 2026-03-18 | Notice of Non-Final Office Action | NFO |
| 2026-03-18 | Non-Final Action | NFIN |
| 2023-09-06 | ITU Unit Action | IUA |
| 2023-08-24 | Statement of Use | SOU |
| 2023-08-24 | Specimen | SPE |
| 2023-08-23 | Change Address or Representation Form | CAR |
USPTO Refusals on Record
- lawful_use_inquiry
- unacceptable_specimen